Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Background and objective Venous thromboembolism (VTE) is associated with long-term clinical and economic burden. Clinical guidelines generally recommend at least 3 months of anticoagulation, but, in clinical practice, concerns over bleeding risk often limit extended treatment. Apixaban was studied for extended VTE treatment in the AMPLIFY-EXT trial, demonstrating superiority to placebo in VTE reduction without increasing risk of major bleeding. This study assessed the long-term clinical and economic benefits of extending treatment with apixaban when clinical equipoise exists compared to standard of care with enoxaparin/warfarin and other novel oral anti-coagulants (NOACs) for the treatment and prevention of recurrent VTE in Canada. Methods A Markov model was developed to follow patients with VTE over their lifetimes. Efficacy and safety for apixaban and enoxaparin/warfarin were based on AMPLIFY and AMPLIFY-EXT, while relative efficacy to other NOACs was synthesized by network meta-analysis (NMA). Dosages for NOACs and enoxaparin/warfarin were based on their respective trials and were given up to 18 months and up to 6 months, followed by no treatment, respectively. Patient quality adjusted life years (QALYs) were based on published studies, and costs for resource utilization were from a Ministry of Health perspective, expressed as 2014 CAD ($). Results Extended treatment with apixaban compared to enoxaparin/warfarin resulted in fewer recurrent VTEs, VTE-related deaths, and bleeding events, but at slightly increased cost. The incremental cost-effectiveness ratio was $4828 per QALY gained. Compared to other NOACs, apixaban had the fewest bleeding events, similar recurrent VTE events, and the lowest overall cost, which was driven by the strong bleeding profile. In scenario analyses of acute and lifetime treatments, apixaban was cost-effective against all strategies. Conclusions Extended treatment with apixaban can offer substantial clinical benefits and is a cost-effective alternative to enoxaparin/warfarin and other NOACs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“All of them suggested that DOACs are costeffective relative to VKA. 100,104-116”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [112]
In the citing paper
“Three analyses showed that the longer course was cost-effective compared with the shorter course of antithrombotic therapy, 112,270, 271”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [112]
In the citing paper
“Three analyses showed cost-effectiveness for the extended strategy compared with the limited antithrombotic strategy, 112,270,271”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [112]
In the citing paper
“Three analyses showed that the extended strategy was cost-effective compared with limited antithrombotic therapy, 112,270,271”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [112]
Citations
Cites
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Masiukiewicz, U., Pak, R., Thompson, J., Raskob, G. E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302507 · Cited by 2,324
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
The Hokusai-VTE Investigators (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306638 · Cited by 1,869
Incidence and mortality of venous thrombosis: a population‐based study
NÆSS, I. A., CHRISTIANSEN, S. C., ROMUNDSTAD, P., CANNEGIETER, S. C., ROSENDAAL, F. R., & HAMMERSTRØM, J. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02450.x · Cited by 1,413
Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension
Ghofrani, H.-A., D'Armini, A. M., Grimminger, F., Hoeper, M. M., Jansa, P., Kim, N. H., Mayer, E., Simonneau, G., Wilkins, M. R., Fritsch, A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209657 · Cited by 1,401
Apixaban for Extended Treatment of Venous Thromboembolism
Agnelli, G., Buller, H. R., Cohen, A., Curto, M., Gallus, A. S., Johnson, M., Porcari, A., Raskob, G. E., & Weitz, J. I. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1207541 · Cited by 1,366
Chronic Thromboembolic Pulmonary Hypertension
Hoeper, M. M., Mayer, E., Simonneau, G., & Rubin, L. J. (2006) · Circulation · doi:10.1161/circulationaha.105.602565 · Cited by 1,148
Research works printed but not linked: 12
- Canadian Agency for Drugs and Technologies in Health., 2013, Antithrombotic agents for the prevention of stroke and systemic embolism in patients with atrial fibrillation
- Canadian Agency for Drugs and Technologies in Health (CADTH). common drug review. Canadian Drug Expert Committee (CDEC) Record of Advice: Rivaroxaban (Xarelto–Bayer Inc.) Indication: Deep Vein Thrombosis without Symptomatic Pulmonary Embolism. Ottawa, ON: CADTH, 2013. https://www.cadth.ca/media/cdr/advice_rec/XareltoRFA_RecordofAdvice_April2013%20(with%20redactions).pdf. Accessed February 26, 2014
- Canadian Agency for Drugs and Technologies in Health (CADTH). Common drug review. Canadian Drug Expert Committee (CDEC) Final Recommendation: RIVAROXABAN (Xarelto–Bayer Inc.) Ottawa, ON: CADTH, 2013. http://www.cadth.ca/media/cdr/complete/cdr_complete_Xarelto-SPAF-RfA_July-22-13_e.pdf. Accessed February 26, 2014
- (OHIP) OMoHaL-TCOHI., 2014, 2014 Schedule of Benefits and Fees
- Parent M., 2010, Pharmactuel, 43, 232
- Statistics Canada., 2012, Canadian Community Health Survey
- Canadian Agency for Drugs and Technologies in Health (CADTH)., 2006, Guidelines for the economic evaluation of health technologies: Canada
- Institut national d’excellence en santé et en services sociaux., 2015, ELIQUIS – Traitement des thromboembolies veineuses et prévention des récidives
- National Institute for Health and Care Excellence (NICE)., 2015, Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism. NICE technology appraisal guidance 341 [TA341]
- 10.1001/archinte.1996.00440150083009 · doi:10.1001/archinte.1996.00440150083009 · Paper page
- Mittmann N, Seung SJ, Sharma M, et al. Impact of disability status on ischaemic stroke costs (Poster P538). Abstract in Stroke 41;4:e390. 2010 International Stroke Congress. San Antonio, TX; 2010
- Statistics Canada., 2014, Consumer Price Index (CPI) for Canada, major components, not seasonally adjusted, historical data. Component: Health and Personal Care. From: Statistics Canada - Catalogue no. 62-001-X. Table 7
Cited by
Ortel, T. L., Neumann, I., Ageno, W., Beyth, R., Clark, N. P., Cuker, A., Hutten, B. A., Jaff, M. R., Manja, V., Schulman, S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001830 · Cited by 1,489
“All of them suggested that DOACs are costeffective relative to VKA.(100,104-116)”
BackgroundMai, V., Bertoletti, L., Cucherat, M., Mainbourg, S., Grangé, C., Provencher, S., & Lega, J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214134 · Cited by 35
Mukdad, M. A., Al‐Badriyeh, D., & Elewa, H. F. (2019) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029619849103 · Cited by 34
“Quon et al concluded that both major and CRNMB events were the main drivers for apixaban being the cost-effective choice among other DOACs.(27) Lanitis et al reported that apixaban would not be considered a dominant choice when the differential price between other DOACs and apixaban increased and when the relative ris…”
BackgroundMethodResultInfluentialXing, J., Yang, L., Yang, Y. K., Zhao, L., Wei, Q., Zhang, J., Zhou, J., & Zhang, H. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.055 · Cited by 24
de Jong, L. A., Dvortsin, E., Janssen, K. J. M., & Postma, M. J. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.12.012 · Cited by 23
“The analysis was based on the results of the AMPLIFY and AMPLIFY-EXT trials and resulted in an ICER of $4,828 per QALY gained.(44) The economic evaluation also found the cost-effectiveness of apixaban compared with other DOACs, which is mostly driven by the reduction of bleeding associated with apixaban use.”
BackgroundMethod
Metadata
- Authors
- Quon, P., Le, H. H., Raymond, V., Mtibaa, M., & Moshyk, A.
- Affiliations
- Pfizer (Canada) (CA)
- Bristol-Myers Squibb (Canada) (CA)
- Corresponding author
- Quon, Peter
- Venue
- Journal of Medical Economics
- Publisher
- Informa UK Limited
- Published
- 2016-02-03
- Volume
- 19
- Issue
- 6
- Pages
- 557-567
- ISSN
- 1369-6998 (ISSN-L)
- 1941-837X
- OpenAlex
- W2262803926
- Cited by
- 12
- References
- 42
- Citations by year
- 2023: 1 · 2021: 1 · 2020: 1 · 2019: 2 · 2017: 5 · 2016: 2
- FWCI
- 3.37
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Medical Economics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb Canada
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- apixaban, long-term anticoagulation, recurrent venous thromboembolism, cost-effectiveness, direct oral anticoagulants, bleeding risk, quality-adjusted life years, Markov model, network meta-analysis
- MeSH terms
- Anticoagulants, Canada, Cost-Benefit Analysis, Female, Hemorrhage, Humans, Male, Markov Chains, Middle Aged, Pyrazoles, Pyridones, Warfarin, Enoxaparin, Quality-Adjusted Life Years, International Normalized Ratio, Venous Thromboembolism
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada. https://app.cochat.ai/papers/10.3111/13696998.2016.1141780
- The paper
- Quon, P., Le, H. H., Raymond, V., Mtibaa, M., & Moshyk, A. (2016). Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada. Journal of Medical Economics. https://doi.org/10.3111/13696998.2016.1141780
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.